INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) https://www.globenewswire.com/news-release/2021/11/22/2338871/0/en/Intellia-Therapeutics-Announces-Expansion-of-Ongoing-Phase-1-Study-of-NTLA-2001-to-Include-Adults-with-Transthyretin-Amyloidosis-with-Cardiomyopathy-ATTR-CM.html Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy

Intellia accelerates plans to evaluate ATTR amyloidosis candidate in cardiomyopathy Nov. 04, 2021 7:59 AM ETIntellia Therapeutics, Inc. (NTLA)By: Jonathan M Block, SA News Editor  Meletios Verras/iStock via Getty Images Intellia Therapeutics (NASDAQ:NTLA) has decided to accelerate plans to evaluate NTLA-2001, its candidate for ATTR amyloidosis, in patients with cardiomyopathy. The company said that based on an interim dataset, it is seeking regulatory feedback on inclusion of cardiomyopathy patients in its current phase 1 study. Intellia is eyeing presenting interim data from part 1, a single-ascending dose portion, and to begin part 2, a single-cohort expansion, in Q1 2022. Elsewhere in the pipeline, the company is planning to begin enrollment in a phase 1 study of NTLA-2002 for hereditary angioedema by the end of the year. Also, by 1H 2022, Intellia's plans to nominate its first allogeneic development candidate. In Q3 2021, Intellia's net loss widened ~158% to $71.6M (0.97 per share basic and diluted) due to a significant decline in collaboration revenue and an increase in R&D expenses

Ist natürlich noch nicht wirklich relevant

Intellia Therapeutics EPS misses by $0.11, misses on revenue Nov. 04, 2021 7:32 AM ETIntellia Therapeutics, Inc. (NTLA)By: Gaurav Batavia, SA News Editor Intellia Therapeutics (NASDAQ:NTLA): Q3 GAAP EPS of -$0.97 misses by $0.11. Revenue of $7.21M (-67.5% Y/Y) misses by $1.45M. Press Release Cash, cash equivalents and marketable securities were $1,148.7 million as of September 30, 2021, compared to $597.4 million as of December 31, 2020. The increase was driven by net proceeds of $648.3 million from a follow-on offering in Q3 2021, $45.3 million of net proceeds from the Company’s “At the Market” agreement, $40.8 million in proceeds from employee-based stock plans, and $4.2 million of funding for a cost-sharing agreement received from Regeneron. These increases were offset in part by cash used to fund operations of approximately $187.3 million.

Etwas ausführlicher: Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis https://www.globenewswire.com/news-release/2021/10/21/2318228/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2001-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis.html

Intellia granted Orphan Drug designation for transthyretin amyloidosis program https://newsfilter.io/a/a34daaacd54413360e2cadfaf0fcfc76 • The FDA has granted Orphan Drug designation to Intellia Therapeutics' (NTLA +0.3%) NTLA-2001 treatment for transthyretin amyloidosis ("ATTR"). • The gene editing therapy use a knockout edit to reduce circulating TTR protein levels. • Intellia is partnered with Regeneron Pharmaceuticals (REGN +0.9%) on NTLA-2001. • NTLA-2001 was granted Orphan Drug designation by the European Commission in March.

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress https://www.globenewswire.com/news-release/2021/10/20/2317270/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-Broad-Genome-Editing-Capabilities-at-the-2021-European-Society-of-Gene-Cell-Therapy-Annual-Congres.html • First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatments • Demonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation • Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous disease-associated protein in non-human primates for the treatment of liver and/or lung manifestations of alpha-1 antitrypsin deficiency (AATD) • Platform advances support acceleration of future drug development candidates from both Intellia’s in vivo and ex vivo research portfolio ...

Kommt dieses Jahr eigentlich noch was an Ergebnissen?🤔

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology https://www.globenewswire.com/news-release/2021/10/13/2313317/0/en/Intellia-Therapeutics-and-SparingVision-Announce-Strategic-Collaboration-to-Develop-Novel-Ocular-Therapies-Using-CRISPR-Cas9-Technology.html • Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise • Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targets • Intellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targets ...

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema https://finance.yahoo.com/news/intellia-therapeutics-receives-authorization-initiate-113000947.html • NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical study • NTLA-2002 is Intellia’s second in vivo CRISPR genome editing therapeutic candidate; program to leverage platform insights gained from ongoing development of NTLA-2001 for transthyretin (ATTR) amyloidosis • On track to initiate patient enrollment by year-end ...

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid https://www.globenewswire.com/news-release/2021/09/16/2298323/0/en/Intellia-Therapeutics-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-for-NTLA-5001-its-CRISPR-Cas9-Engineered-TCR-T-Cell-Candidate-for-Acute-Myeloid-Leukemia.html • NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study • NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors • Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end ...

🧐🧐🧐

Hey ✌🏼

Es ist so anstrengend zu Sehen wie eine Aktie steigt über mehrere Tage und einfach mal an einem Tag das selbe wieder verliert 🙄🧐

Bobby, auch hier Danke für den Link . Auch hier bin ich investiert 👍

Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress Established proof of concept for the Company’s modular in vivo delivery platform with first-ever clinical data from systemically administered CRISPR genome editing candidate in humans Interim Phase 1 data from first two cohorts show NTLA-2001 was well-tolerated and achieved deep TTR reduction, with a maximum 96% serum TTR reduction by day 28, demonstrating potential as single-dose treatment for transthyretin (ATTR) amyloidosis; plan to report additional data from ongoing study this year Plans to initiate first-in-human studies for both NTLA-2002 for hereditary angioedema (HAE) and NTLA-5001 for acute myeloid leukemia (AML) this year Launched CAR T-cell company with Blackstone Life Sciences and Cellex Cell Professionals; concurrent agreement with Cellex gives Intellia access to donor cells and dedicated manufacturing capacity to support wholly-owned ex vivo portfolio Ended the quarter with strong cash position of $551.3 million, and raised an additional $648.1 million of net proceeds from follow-on offering in July